You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

576 Results
Document
Drug
Other Name(s): Vitrakvi®
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Oct 2025
Guidelines and Advice
Status: Current
ID: GL 1-25
Version: N/A
Mar 2023
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    letrozole
New
Dec 2025

Pages